IBDEI24R ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,36125,1,3,0)
 ;;=3^Thoracogenic Scoliosis,Thoracic Region
 ;;^UTILITY(U,$J,358.3,36125,1,4,0)
 ;;=4^M41.34
 ;;^UTILITY(U,$J,358.3,36125,2)
 ;;=^5011865
 ;;^UTILITY(U,$J,358.3,36126,0)
 ;;=R10.9^^134^1742^1
 ;;^UTILITY(U,$J,358.3,36126,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36126,1,3,0)
 ;;=3^Abdominal Pain,Unspec
 ;;^UTILITY(U,$J,358.3,36126,1,4,0)
 ;;=4^R10.9
 ;;^UTILITY(U,$J,358.3,36126,2)
 ;;=^5019230
 ;;^UTILITY(U,$J,358.3,36127,0)
 ;;=N39.41^^134^1742^73
 ;;^UTILITY(U,$J,358.3,36127,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36127,1,3,0)
 ;;=3^Urge Incontinence
 ;;^UTILITY(U,$J,358.3,36127,1,4,0)
 ;;=4^N39.41
 ;;^UTILITY(U,$J,358.3,36127,2)
 ;;=^5015680
 ;;^UTILITY(U,$J,358.3,36128,0)
 ;;=G44.1^^134^1742^74
 ;;^UTILITY(U,$J,358.3,36128,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36128,1,3,0)
 ;;=3^Vascular Headache NEC
 ;;^UTILITY(U,$J,358.3,36128,1,4,0)
 ;;=4^G44.1
 ;;^UTILITY(U,$J,358.3,36128,2)
 ;;=^5003934
 ;;^UTILITY(U,$J,358.3,36129,0)
 ;;=R53.1^^134^1742^75
 ;;^UTILITY(U,$J,358.3,36129,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36129,1,3,0)
 ;;=3^Weakness
 ;;^UTILITY(U,$J,358.3,36129,1,4,0)
 ;;=4^R53.1
 ;;^UTILITY(U,$J,358.3,36129,2)
 ;;=^5019516
 ;;^UTILITY(U,$J,358.3,36130,0)
 ;;=B02.9^^134^1742^76
 ;;^UTILITY(U,$J,358.3,36130,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36130,1,3,0)
 ;;=3^Zoster w/o Complications
 ;;^UTILITY(U,$J,358.3,36130,1,4,0)
 ;;=4^B02.9
 ;;^UTILITY(U,$J,358.3,36130,2)
 ;;=^5000501
 ;;^UTILITY(U,$J,358.3,36131,0)
 ;;=90732^^135^1743^6
 ;;^UTILITY(U,$J,358.3,36131,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,36131,1,1,0)
 ;;=1^90732
 ;;^UTILITY(U,$J,358.3,36131,1,3,0)
 ;;=3^PNEUMOVAX
 ;;^UTILITY(U,$J,358.3,36132,0)
 ;;=86580^^135^1743^7
 ;;^UTILITY(U,$J,358.3,36132,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,36132,1,1,0)
 ;;=1^86580
 ;;^UTILITY(U,$J,358.3,36132,1,3,0)
 ;;=3^PPD WITH CONTROLS
 ;;^UTILITY(U,$J,358.3,36133,0)
 ;;=90658^^135^1743^3^^^^1
 ;;^UTILITY(U,$J,358.3,36133,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,36133,1,1,0)
 ;;=1^90658
 ;;^UTILITY(U,$J,358.3,36133,1,3,0)
 ;;=3^FLU VACCINE IM (FLULAVAL)
 ;;^UTILITY(U,$J,358.3,36134,0)
 ;;=90471^^135^1743^1^^^^1
 ;;^UTILITY(U,$J,358.3,36134,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,36134,1,1,0)
 ;;=1^90471
 ;;^UTILITY(U,$J,358.3,36134,1,3,0)
 ;;=3^IMMUNIZATION ADMIN, SINGLE
 ;;^UTILITY(U,$J,358.3,36135,0)
 ;;=90472^^135^1743^2^^^^1
 ;;^UTILITY(U,$J,358.3,36135,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,36135,1,1,0)
 ;;=1^90472
 ;;^UTILITY(U,$J,358.3,36135,1,3,0)
 ;;=3^IMMUNIZATION ADMIN, 2+
 ;;^UTILITY(U,$J,358.3,36136,0)
 ;;=86486^^135^1743^8^^^^1
 ;;^UTILITY(U,$J,358.3,36136,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,36136,1,1,0)
 ;;=1^86486
 ;;^UTILITY(U,$J,358.3,36136,1,3,0)
 ;;=3^SKIN TEST, NOS ANTIGEN
 ;;^UTILITY(U,$J,358.3,36137,0)
 ;;=90656^^135^1743^4^^^^1
 ;;^UTILITY(U,$J,358.3,36137,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,36137,1,1,0)
 ;;=1^90656
 ;;^UTILITY(U,$J,358.3,36137,1,3,0)
 ;;=3^FLU VACC SGL DOSE SYR (AFLURIA)
 ;;^UTILITY(U,$J,358.3,36138,0)
 ;;=90662^^135^1743^5^^^^1
 ;;^UTILITY(U,$J,358.3,36138,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,36138,1,1,0)
 ;;=1^90662
 ;;^UTILITY(U,$J,358.3,36138,1,3,0)
 ;;=3^FLU VACC HIGH DOSE (FLUZONE)
 ;;^UTILITY(U,$J,358.3,36139,0)
 ;;=94642^^135^1744^3
 ;;^UTILITY(U,$J,358.3,36139,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,36139,1,1,0)
 ;;=1^94642
 ;;^UTILITY(U,$J,358.3,36139,1,3,0)
 ;;=3^PENTAMIDINE THERAPY
 ;;^UTILITY(U,$J,358.3,36140,0)
 ;;=94664^^135^1744^1
 ;;^UTILITY(U,$J,358.3,36140,1,0)
 ;;=^358.31IA^3^2
